Axsome Therapeutics, Inc. $AXSM Shares Sold by Integrity Alliance LLC.

Integrity Alliance LLC. lessened its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 48.5% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 4,625 shares of the company’s stock after selling 4,358 shares during the period. Integrity Alliance LLC.’s holdings in Axsome Therapeutics were worth $853,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of the company. Hollencrest Capital Management lifted its stake in shares of Axsome Therapeutics by 400.0% during the 1st quarter. Hollencrest Capital Management now owns 200 shares of the company’s stock worth $34,000 after buying an additional 160 shares during the last quarter. ABS Direct Equity Fund LLC bought a new stake in Axsome Therapeutics during the 2nd quarter valued at $60,000. Silvant Capital Management LLC purchased a new stake in shares of Axsome Therapeutics during the 2nd quarter valued at $66,000. GAMMA Investing LLC increased its stake in shares of Axsome Therapeutics by 19.9% during the third quarter. GAMMA Investing LLC now owns 416 shares of the company’s stock valued at $77,000 after buying an additional 69 shares during the period. Finally, Parkside Financial Bank & Trust increased its position in shares of Axsome Therapeutics by 505.4% during the second quarter. Parkside Financial Bank & Trust now owns 339 shares of the company’s stock valued at $83,000 after acquiring an additional 283 shares in the last quarter. Institutional investors own 81.49% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Truist Financial upped their target price on shares of Axsome Therapeutics from $200.00 to $285.00 and gave the stock a “buy” rating in a research note on Wednesday, September 23rd. BMO Capital Markets assumed coverage on Axsome Therapeutics in a report on Monday, July 20th. They issued an “outperform” rating and a $310.00 target price for the company. Guggenheim cut their price target on shares of Axsome Therapeutics from $275.00 to $250.00 and set a “buy” rating on the stock in a report on Tuesday. Deutsche Bank Aktiengesellschaft lowered their price objective on shares of Axsome Therapeutics from $280.00 to $267.00 and set a “buy” rating on the stock in a research note on Tuesday, September 29th. Finally, Wells Fargo & Company reiterated an “outperform” rating on shares of Axsome Therapeutics in a research report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $267.58.

Axsome Therapeutics Trading Up 2.0%

Axsome Therapeutics stock opened at $132.37 on Friday. The company has a quick ratio of 1.34, a current ratio of 1.43 and a debt-to-equity ratio of 1.52. The firm’s fifty day moving average price is $177.62 and its 200-day moving average price is $197.87. Axsome Therapeutics, Inc. has a fifty-two week low of $123.00 and a fifty-two week high of $260.19.

Axsome Therapeutics (NASDAQ:AXSM) last posted its earnings results on Monday, November 2nd. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.63) by $0.38. The business had revenue of $259.69 million for the quarter, compared to analysts’ expectations of $249.19 million. Axsome Therapeutics had a negative net margin of 18.18% and a negative return on equity of 218.52%. The business’s revenue for the quarter was up 51.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.94) EPS. As a group, analysts forecast that Axsome Therapeutics, Inc. will post -2.57 earnings per share for the current year.

Insider Activity

In other Axsome Therapeutics news, COO Mark Jacobson sold 10,000 shares of the firm’s stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $208.65, for a total transaction of $2,086,500.00. Following the completion of the transaction, the chief operating officer directly owned 10,000 shares in the company, valued at approximately $2,086,500. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 20.60% of the company’s stock.

About Axsome Therapeutics

Axsome Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system (CNS) disorders. Founded in 2012 and headquartered in New York, the company develops medicines for conditions with significant unmet medical needs, including depression, narcolepsy, excessive daytime sleepiness, and other neurological disorders.

Axsome’s commercial products include Auvelity (dextromethorphan and bupropion), an oral treatment approved in the United States for major depressive disorder in adults, and Sunosi (solriamfetol), a therapy for excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea.